Boehringer recently reported positive results from the Beamion LUNG-1 trial evaluating zongertinib in treatment-naïve patients with advanced NSCLC at ESMO 2025. The company is pursuing regulatory ...

What Is Hernexeos, and Why Does It Matter? Hernexeos (zongertinib) is a new pill for adults with a type of advanced lung cancer called non-small-cell lung cancer (NSCLC) that has a HER2 gene mutation ...

The MarketWatch News Department was not involved in the creation of this content. This press release is not intended for UK media. -- HERNEXEOS(R) (zongertinib tablets) approved based on an objective ...

Breast cancer is a complex disease with numerous classifications. Understanding risk factors such as age, family history, genetic mutations such as breast cancer gene 1/breast cancer gene 2 ...

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

INGELHEIM, Germany and RIDGEFIELD, Conn., Oct. 17, 2025 /PRNewswire/ -- Boehringer Ingelheim reported positive results from the Beamion LUNG-1 trial evaluating HERNEXEOS ® (zongertinib tablets) in ...

Breast cancer is a complex disease with many types. Understanding the specific type and classification of the breast cancer you have is crucial so that you can fully participate as an informed partner ...